Finally, the newer class of glucose-lowering drugs for the treatment of type 2 diabetes, sodium-glucose co-transporter 2 (SGLT-2) inhibitors, have been associated with increased plasma glucagon concentrations. This evidence concerns the gene GCG and type 2 diabetes mellitus.